UB-VV100
Overview:
Chimeric Antigen Receptor (CAR) T-cells for immunotherapy of cancer are being developed. These CAR T-cells overcome several limitations of current strategies including the ability to tune CAR T-cell activity and even completely “turn-off” the activated CAR T-cells. UB-TT170 is an in vivo engineered CD19-targeted CAR T cell for the treatment of B cell malignancies.